4QG Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.10 |
| 52 Week High | NOK 0.23 |
| 52 Week Low | NOK 0.091 |
| Beta | 1.63 |
| 1 Month Change | -17.62% |
| 3 Month Change | -32.49% |
| 1 Year Change | -39.16% |
| 3 Year Change | -92.10% |
| 5 Year Change | -98.58% |
| Change since IPO | -93.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | 2.5% | -0.4% |
| 1Y | -39.2% | -10.2% | 7.9% |
Return vs Industry: 4QG underperformed the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: 4QG underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 4QG volatility | |
|---|---|
| 4QG Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4QG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4QG's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.
PCI Biotech Holding ASA Fundamentals Summary
| 4QG fundamental statistics | |
|---|---|
| Market cap | €4.43m |
| Earnings (TTM) | -€1.36m |
| Revenue (TTM) | €512.60k |
8.6x
P/S Ratio-3.3x
P/E RatioIs 4QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4QG income statement (TTM) | |
|---|---|
| Revenue | NOK 6.00m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 6.00m |
| Other Expenses | NOK 21.91m |
| Earnings | -NOK 15.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -265.24% |
| Debt/Equity Ratio | 0% |
How did 4QG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 05:56 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PCI Biotech Holding ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |